Omeros (NASDAQ:OMER) Stock Keeps “Buy” Rating at HC Wainwright
by Michael Walen · The Markets DailyOmeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. HC Wainwright‘s price objective points to a potential upside of 149.34% from the company’s current price.
A number of other equities research analysts have also recently commented on OMER. Cantor Fitzgerald reissued an “overweight” rating and issued a $22.00 price objective on shares of Omeros in a research note on Wednesday, October 14th. Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.33.
Check Out Our Latest Analysis on Omeros
Omeros Price Performance
Shares of OMER traded down $3.44 during trading hours on Tuesday, hitting $13.23. The stock had a trading volume of 1,131,558 shares, compared to its average volume of 1,592,276. The firm has a 50 day simple moving average of $18.22 and a 200-day simple moving average of $13.76. The firm has a market capitalization of $958.08 million, a P/E ratio of 10.47 and a beta of 2.96. Omeros has a 1-year low of $6.70 and a 1-year high of $21.24.
Omeros (NASDAQ:OMER – Get Free Report) last issued its earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. The firm had revenue of $35.93 million during the quarter, compared to the consensus estimate of $37.28 million. Equities analysts predict that Omeros will post -0.37 EPS for the current fiscal year.
Insider Buying and Selling
In other news, Director Thomas J. Cable sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares of the company’s stock, valued at $646,986.15. This represents a 29.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Arnold C. Hanish sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $94,750. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 100,906 shares of company stock worth $1,904,955 over the last 90 days. Company insiders own 10.50% of the company’s stock.
Institutional Investors Weigh In On Omeros
A number of institutional investors and hedge funds have recently bought and sold shares of OMER. Aquatic Capital Management LLC bought a new stake in shares of Omeros in the 3rd quarter worth $733,000. Goldman Sachs Group Inc. raised its holdings in shares of Omeros by 151.6% in the third quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 238,024 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Omeros during the third quarter valued at about $3,387,000. Caxton Associates LLP bought a new position in shares of Omeros during the third quarter valued at about $284,000. Finally, Hohimer Wealth Management LLC purchased a new position in Omeros during the third quarter worth about $419,000. 48.79% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting Omeros
Here are a few of the latest headlines about OMER:
- Positive Sentiment: Omeros reported earnings of $0.06 per share, above analyst expectations. It also said YARTEMLEA generated $41.8 million in gross revenue in the quarter, highlighting demand for its approved TA-TMA treatment. Omeros third-quarter results
- Neutral Sentiment: The company expects $5 million to $6 million of income from discontinued operations in the fourth quarter while continuing to build YARTEMLEA education and outpatient use. The outlook may help near-term results, though the article does not establish the longer-term impact. Q4 outlook and YARTEMLEA expansion
- Negative Sentiment: Quarterly revenue was $35.9 million, below the roughly $37.3 million analyst estimate. Market coverage also highlighted a wider third-quarter loss, tempering the positive per-share earnings surprise and contributing to pressure on OMER shares. Report on Omeros’s wider third-quarter loss
About Omeros
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Further Reading
- Five stocks we like better than Omeros
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake